|TEV||0||TEV/EBIT||0||TTM 2019-03-31, in MM, except price, ratios|
|Item 5.03Amendments To Articles of Incorporation or Bylaws, Change of Fiscal Year|
|Item 9.01Financial Statements and Exhibits.|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 14, 2018 (November 7, 2018)
GUIDED THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction of incorporation)||(Commission File Number)||(IRS Employer Identification No.)|
5835 Peachtree Corners East, Suite B
Norcross, Georgia 30092
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (770) 242-8723
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|[ ]||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|[ ]||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|[ ]||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|[ ]||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □
|Item 5.03||Amendments to Articles of Incorporation or Bylaws, Change of Fiscal Year|
On November 7, 2018, Guided Therapeutics, Inc., a Delaware corporation (the “Company”) filed with the Secretary of State of Delaware, a Certificate of Amendment to the Restated Certificate of Incorporation (the “Certificate”) to increase the Company’s authorized common stock, par value $0.001 per share, from 1,000,000,000 shares to 3,000,000,000 shares. A copy of the Certificate is attached hereto as Exhibit 3.1 and is incorporated by reference herein.
|Item 9.01||Financial Statements and Exhibits.|
Title of Document
|3.1||Certificate of Amendment|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|GUIDED THERAPEUTICS, INC.|
|Date: November 14, 2018||By: /s/ Gene S. Cartwright, Ph.D.|
|Name: Gene S. Cartwright, Ph.D.|
|Title: President, Chief Executive Officer and Director|